Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations.

Novo Nordisk shares drop more than 4% on disappointing obesity pill data

Corbus Pharmaceuticals Holdings

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects

The blockbuster drug strengthens its case that obesity drugs have health benefits beyond weight-loss.

Novo's Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

The European Medicines Agency backed the use of Novo Nordisk's Wegovy in patients with an obesity-related heart condition, the Danish drugmaker said on Thursday.

EU regulator backs use of Novo's Wegovy for obesity-related heart condition

Wegovy ® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function

Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Supply constraints for the obesity business are easing, and we should see growth pick up in the second half of the year and more so in 2025. Oral amycretin candidate data look good, with no new safety and tolerability signals.

Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential

Novo Nordisk and Korro Bio just signed a big collaboration deal. The pair aim to develop medicines involving mRNA, which is Moderna's specialty.

Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may be rising significantly. Medicare and Medicaid are covering a significant number of the prescriptions of these drugs, with Medicaid covering Wegovy in 20 states.

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership combines NanoVation Therapeutics' proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside of the liver.

NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases

Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive.

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports

DexCom

Novo Nordisk is the leader in developing drugs in a fast-growing area. DexCom's recent drop doesn't take away from its long runway for growth.

2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200

Novo Nordisk (NVO) reachead $136.66 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.

Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

Altimmune

Structure Therapeutics Inc

Eli Lilly

Viking Therapeutics

Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.

Five Top Obesity Stocks to Buy and Hold Long Term

Roche Holding AG

The company's stock was falling after a report detailing side effects from its once-daily weight-loss pill.

Roche Setback Is Big for Eli Lilly, Novo Nordisk as Obesity Drug Battle Ramps Up

As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin.

2 Weight Loss Drug Stocks Worth Stashing Away for Years

Novo Nordisk stock rose moderately Wednesday after the pharma giant said its new weight-loss drug, amycretin, outperformed Wegovy.

Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise

Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition from Mounjaro maker Eli Lilly, pharma titans like Pfizer and biotech upstarts.

Novo Nordisk's New Obesity Pill Beats Wegovy In Early Trial

A late-stage clinical trial showed drug helped children aged 6-11 reduce their BMI.

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids

A recent study has found that liraglutide, a drug approved for obesity treatment in adults and teens, is safe and effective for children as young as six when combined with diet and exercise. The research, presented at a medical conference and published in the New England Journal of Medicine, showed that liraglutide reduced body mass and slowed weight gain in children aged 6 to 11.

Weight loss jabs of six-year-olds? Here's the latest clinical findings

Regeneron Pharmaceuticals

Here are biotech stocks to check out this month.

2 Biotech Stocks To Watch In September 2024

Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects, the company said on Wednesday.

News for Novo Nordisk Stock (NVO)